Alnylam Pharmaceuticals (ALNY) Non-Current Deffered Revenue (2016 - 2024)
Alnylam Pharmaceuticals (ALNY) has disclosed Non-Current Deffered Revenue for 15 consecutive years, with $1.0 million as the latest value for Q3 2024.
- For the quarter ending Q3 2024, Non-Current Deffered Revenue fell 99.48% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Sep 2024, down 99.48%, and an annual FY2023 reading of $188.2 million, down 2.9% over the prior year.
- Non-Current Deffered Revenue was $1.0 million for Q3 2024 at Alnylam Pharmaceuticals, down from $2.4 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $306.1 million in Q1 2020 and bottomed at $1.0 million in Q3 2024.
- Average Non-Current Deffered Revenue over 5 years is $180.9 million, with a median of $191.3 million recorded in 2023.
- The sharpest move saw Non-Current Deffered Revenue surged 63942.68% in 2020, then tumbled 99.48% in 2024.
- Year by year, Non-Current Deffered Revenue stood at $225.1 million in 2020, then crashed by 32.31% to $152.4 million in 2021, then increased by 27.19% to $193.8 million in 2022, then dropped by 2.9% to $188.2 million in 2023, then crashed by 99.46% to $1.0 million in 2024.
- Business Quant data shows Non-Current Deffered Revenue for ALNY at $1.0 million in Q3 2024, $2.4 million in Q2 2024, and $185.5 million in Q1 2024.